2022年4月15日金曜日
- We are a multicultural and international organization with offices in four ... global health, emerging infectious disease nursing, medical anthropology, ...
- Saylors has an energetic commitment to multilateral research, coordinating international programs through the Company's offices in DRC, Ukraine, and the US.
We have a vast collaborator network throughout Africa, Southeast Asia, Latin America, and Eastern Europe.
Our office and available laboratory space in Kinshasa, Democratic Republic of Congo, hosted within the national Ministry of Health biomedical reference lab (INRB), provides a valuable springboard for scientific initiatives. We also maintain an office in Sierra Leone and a large collaborative network in Cameroon, with experts based at the Cameroon military health research center (CRESAR), as well as within various collaborating non-governmental organizations in country. Labyrinth’s global reach is further expanded through our office in Kyiv, Ukraine, a gateway to Eastern Europe. Built on successful implementation of projects that span Ukraine, Armenia, and Azerbaijan, we engage Ministries and scientists in collaborative pursuits throughout the region.
UKRAINE
Through our Ukraine office, Labyrinth leverages decade-long experience, deep network, and stakeholder relationships that build capacity and capability supporting health initiatives in Eastern Europe. Our experts are well versed in requirements for successful and seamless integration to address Clients’ mission objectives.https://web.archive.org/web/20210817140835/https://www.labyrinthgh.com/where-we-work
EXCLUSIVE: Hunter Biden DID help secure millions in funding for US contractor in Ukraine specializing in deadly pathogen research, laptop emails reveal, raising more questions about the disgraced son of then vice president
- The Russian government held a press conference Thursday claiming that Hunter Biden helped finance a US military 'bioweapons' research program in Ukraine
- However the allegations were branded a brazen propaganda ploy to justify president Vladimir Putin's invasion of Ukraine and sow discord in the US
- But emails and correspondence obtained by DailyMail.com from Hunter's abandoned laptop show the claims may well be true
- The emails show Hunter helped secure millions of dollars of funding for Metabiota, a Department of Defense contractor specializing in research on pandemic-causing diseases
- He also introduced Metabiota to an allegedly corrupt Ukrainian gas firm, Burisma, for a 'science project' involving high biosecurity level labs in Ukraine
- The president's son and his colleagues invested $500,000 in Metabiota through their firm Rosemont Seneca Technology Partners
- They raised several million dollars of funding for the company from investment giants including Goldman Sachs
Moscow’s claim that Hunter Biden helped finance a US military 'bioweapons' research program in Ukraine is at least partially true, according to new emails obtained exclusively by DailyMail.com.
The commander of the Russian Nuclear, Biological and Chemical Protection Forces, claimed there was a 'scheme of interaction between US government agencies and Ukrainian biological objects' and pointed to the 'financing of such activities by structures close to the current US leadership, in particular the investment fund Rosemont Seneca, which is headed by Hunter Biden.'
Intelligence experts say the Russian military leader's allegations were a brazen propaganda ploy to justify president Vladimir Putin's invasion of Ukraine and sow discord in the US.
But emails from Hunter's abandoned laptop show he helped secure millions of dollars of funding for Metabiota, a Department of Defense contractor specializing in research on pandemic-causing diseases that could be used as bioweapons.
He also introduced Metabiota to an allegedly corrupt Ukrainian gas firm, Burisma, for a 'science project' involving high biosecurity level labs in Ukraine.
And although Metabiota is ostensibly a medical data company, its vice president emailed Hunter in 2014 describing how they could 'assert Ukraine's cultural and economic independence from Russia' – an unusual goal for a biotech firm.
Emails and defense contract data reviewed by DailyMail.com suggest that Hunter had a prominent role in making sure Metabiota was able to conduct its pathogen research just a few hundred miles from the border with Russia.The project turned into a national security liability for Ukraine when Russian forces invaded the country last month.
Metabiota has worked in Ukraine for Black & Veatch, a US defense contractor with deep ties to military intelligence agencies, which built secure labs in Ukraine that analyzed killer diseases and bioweapons.
Earlier this month US officials warned congress that 'Russian forces may be seeking to gain control' of these 'biological research facilities', prompting fears that deadly and even engineered pathogens could fall into Russian hands.
Hunter and his colleagues at his investment firm Rosemont Seneca Technology Partners (RSTP) routinely raised millions of dollars for technology companies, hoping the firms would take off and make them all fortunes.
Metabiota was one of those firms. Emails between Hunter and his colleagues excitedly discuss how the company's monitoring of medical data could become an essential tool for governments and companies looking to spot outbreaks of infectious diseases.
The president's son and his colleagues invested $500,000 in Metabiota through their firm Rosemont Seneca Technology Partners.
They raised several million dollars of funding for the company from investment giants including Goldman Sachs.
But emails show Hunter was also particularly involved in Metabiota's operations in Ukraine.
Hunter's pitches to investors claimed that they not only organized funding for the firm, they also helped it 'get new customers' including 'government agencies in case of Metabiota'.
He and his business partner Eric Schwerin even discussed subletting their office space to the firm in April 2014, their emails reveal.
That month, Metabiota vice president Mary Guttieri wrote a memo to Hunter outlining how they could 'assert Ukraine's cultural and economic independence from Russia'.
'Thanks so much for taking time out of your intense schedule to meet with Kathy [Dimeo, Metabiota executive] and I on Tuesday. We very much enjoyed our discussion,' Guttieri wrote.
'As promised, I've prepared the attached memo, which provides an overview of Metabiota, our engagement in Ukraine, and how we can potentially leverage our team, networks, and concepts to assert Ukraine's cultural and economic independence from Russia and continued integration into Western society.'
Former senior CIA officer Sam Faddis, who has reviewed emails on Hunter's laptop, told DailyMail.com that the offer to help assert Ukraine's independence was odd for a biotech executive.
'It raises the question, what is the real purpose of this venture? It's very odd,' he said
Guttieri had a leading role in Metabiota's Ukraine operations, meeting with other company executives and US and Ukrainian military officials in October 2016 to discuss 'cooperation in surveillance and prevention of especially dangerous infectious diseases, including zoonotic diseases in Ukraine and neighboring countries' according to a 2016 report by the Science and Technology Center in Ukraine.
At the time, Hunter was serving as a board member of Ukrainian gas firm Burisma, owned by former top government official and allegedly corrupt billionaire Mikolay Zlochevsky.
Four days after Guttieri's April 2014 email, Burisma executive Vadym Pozharskyi wrote to Hunter revealing that the then-Vice President's son had pitched a 'science project' involving Burisma and Metabiota in Ukraine.
'Please find few initial points to be discussed for the purposes of analyzing the potential of this as you called, 'Science Ukraine' project,' Pozharskyi wrote.
'As I understand the Metabiota was a subcontract to principal contactor of the DoD B&V [Black & Veatch].
'What kind of partnership Metabiota is looking for in Ukraine? From potential non-governmental player in Kiev? Rebuilt the ties with respective ministries in Ukraine, and on the basis of that reinstate the financing from the B&V? Or they look for partnership in managing projects in Ukraine, PR with Government institutions here, financing of the projects?'
Faddis told DailyMail.com that the attempt to get Metabiota to form a partnership with Burisma was a perplexing and worrying revelation.
'His father was the Vice President of the United States and in charge of relations with Ukraine. So why was Hunter not only on the board of a suspect Ukrainian gas firm, but also hooked them up with a company working on bioweapons research?' Faddis said.
'It's an obvious Russian propaganda attempt to take advantage of this. But it doesn't change the fact that there does seem to be something that needs to be explored here.
'The DoD position is that there's nothing nefarious here, this is pandemic early warning research. We don't know for sure that's all that was going on.
'But the question still remains: why is Hunter Biden in the middle of all this? Why is the disgraced son of the vice president at the heart of this – the guy with no discernible skills and a cocaine habit.'
Pozharsky said in his email to Hunter that he had encountered such biological research projects before in his former job as a Ukrainian government official, and claimed that B&V worked on 'similar or the same projects' as the proposed contract for Metabiota.
Government spending records show the Department of Defense awarded an $18.4million contract to Metabiota between February 2014 and November 2016, with $307,091 earmarked for 'Ukraine research projects'.
The US Defense Threat Reduction Agency (DTRA) also commissioned B&V to build a Biological Safety Level 3 laboratory in Odessa, Ukraine in 2010, which 'provided enhanced equipment and training to effectively, safely and securely identify especially dangerous pathogens' according to a company press release.
Such labs are used to 'study infectious agents or toxins that may be transmitted through the air and cause potentially lethal infections,' the US Department of Health and Human Services says.
B&V was awarded a further five-year $85million contract in 2012.
In another sign of the deep ties between Metabiota and the Department of Defense, Hunter's RSTP business partner Rob Walker said he would 'have a friend reach out to DoD on the down low', in order to prove the company's bona fides to top prospective investors Goldman Sachs and Morgan Stanley in October 2014.
RSTP was a subsidiary of Rosemont Capital, an investment company founded by Hunter and former Secretary of State John Kerry's stepson Chris Heinz in 2009.
Metabiota also has close ties to the Wuhan Institute of Virology (WIV), suspected to be the source of the COVID-19 outbreak.
WIV was a hotspot for controversial 'gain of function' research that can create super-strength viruses.
Chinese scientists performed gain of function research on coronaviruses at the WIV, working alongside a US-backed organization EcoHealth Alliance that has since drawn intense scrutiny over its coronavirus research since the COVID-19 pandemic.
Researchers from the Wuhan institute, Metabiota and EcoHealth Alliance published a study together in 2014 on infectious diseases from bats in China, which notes that tests were performed at the WIV.
Shi Zhengli, the WIV Director of the Center for Emerging Infectious Diseases who became dubbed the 'bat lady' for her central role in bat coronavirus research at the lab, was a contributor to the paper.
Metabiota has been an official partner of EcoHealth Alliance since 2014, according to its website.
https://www.dailymail.co.uk/news/article-10652127/Hunter-Biden-helped-secure-millions-funding-military-biotech-research-program-Ukraine.html
Metabiota Awarded Funding By European Commission To Help in Fight Against Ebola
Part of the EU Framework Programme for Research and Innovation - Horizon 2020
Dec 03, 2014, 09:30 ET
SAN FRANCISCO, Dec. 3, 2014 /PRNewswire/ -- Metabiota Inc., announced today that the European Commission (EC) has awarded funding to the Company to work with European and Canadian collaborators on an advanced project aimed at validating both a highly sensitive diagnostic test and an extremely promising treatment for Ebola virus disease (EVD), which will help decrease the number of deaths and prevent further spread of the disease. Funding is based on a grant through The EU Framework Programme for Research and Innovation - Horizon 2020, the largest EC Research and Innovation Programme, with nearly €80 billion of available funding over the next seven years. Metabiota is the first U.S. subcontractor to be selected by the EC for an important endeavor of this nature.
Logo - http://photos.prnewswire.com/prnh/20141202/161970LOGO
The 2014 Ebola epidemic is the largest on record, with more than 15,000 reported cases and over 5,000 deaths to date, according to the World Health Organization (WHO). Metabiota has played a pivotal role in the fight against Ebola, having led the diagnostic efforts for all of Sierra Leone and, in this capacity, having identified the first confirmed in-country case.
"The EC is embarking upon an important initiative in the fight against Ebola, and we are honored to be among the first U.S. companies to be selected to join the team of esteemed collaborators," said Mary Guttieri, Executive Vice President of Metabiota. "This recognition is validation of the work that our dedicated team has been doing in West Africa for the past several years and, more importantly, the critical contributions our team has made in supporting the current outbreak."
The EC funded project reflects a collaborative effort, crystallizing synergy between complementary experts from private and public sectors at the forefront of the epidemic. The international consortium is led by the French research governmental institution, the Institut de Recherche pour le Developpement (IRD), France; with collaborators from academic institutions, including Ben-Gurion University of the Negev (BGU), Israel; the Istituto Nazionale Malattie Infettive L.Spallanzani – IRCCS (INMI), Italy; the Institut Pasteur (IP), France; University of Manitoba (UM), Canada; and private companies, including Fab'entech, France; Orion Integrated Biosciences Inc. (OIB), U.S.; and Metabiota Inc., U.S.; as well as the Ministries of Health of Sierra Leone and Guinea.
For its part, Metabiota will contribute in-country field experience to help improve diagnostics and develop a highly promising antibody treatment, which has been successfully used for other infectious diseases validated by the European Commission and WHO.
Since 2009, Metabiota has been supporting in-country surveillance, outbreak investigation and response networks, and local laboratories in the small West African nation of Sierra Leone. In 2012, the Ministry of Health and Sanitation (MOHS)-Metabiota Viral Hemorrhagic Fever (VHF) laboratory (Kenema, Sierra Leone) was established and became the focal point for diagnosing VHFs, including the five species of Ebola virus. When the threat of Ebola in West Africa emerged early in 2014, the MOHS-Metabiota lab quickly adapted diagnostics to subsequently enable identification of the Ebola virus Zaire species, the deadly strain circulating in West Africa.
As the only in-country laboratory capable of performing the most comprehensive and thorough surveillance and testing, the MOHS-Metabiota lab became the reference laboratory for EVD diagnostics in Sierra Leone and continues to play a key role in responding to the worst ever Ebola epidemic.
About Horizon 2020 and The EU Framework Programme for Research and Innovation
Horizon 2020 is the largest EU Research and Innovation Program. The Program, supported by Europe's leaders and Members of the European Parliament, is structured to enable breakthroughs and discoveries to secure Europe's global competitiveness. Serving as the driver for the present award for Metabiota and the international consortium partners, this Program has allocated specific funding (Innovative Medical Initiative) to contribute to the EVD response in Africa in order to intervene rapidly, efficiently, and with a sense of durability within the threatened countries.
About Metabiota
Metabiota develops systems to mitigate microbial threats. The company specializes in disease and pathogen detection, evaluation, and response through the integration of field and lab research with health data analytics. Metabiota has a demonstrated track record in international collaboration, scientific and public health surveillance capacity building, and research with high public health impact.
In addition, several of the Company's past and current initiatives have been supported by Google.org, the Skoll Foundation, as well as the U.S. Government.
For more information, visit http://metabiota.com/.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/metabiota-awarded-funding-by-european-commission-to-help-in-fight-against-ebola-300003700.html
SOURCE Metabiota Inc.
Related Links
まあアウト確定でしょうなあ・・・（爆ｗｗｗｗｗｗｗｗ
2 件のコメント:
> Labyrinth Global Health
世界中の人間の健康は迷宮の中で迷走中ですってかｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗｗ
団長御指摘通りがまた此処にw
プーチン閣下が手を汚して焦土区
梅田爺はポジショントークしながら
武器供与も焦土区が進むようにって
お願いしてJPDGZナウなのかもね(苦
コメントを投稿